Enanta Pharmaceuticals (ENTA) said Thursday that a phase 2a study evaluating EDP-323 in adults with respiratory syncytial virus, or RSV, met its primary and secondary endpoints.

Reductions of 85% to 87% in viral load area under the curve, 97% to 98% in infectious viral load AUC, and 66% to 78% in overall symptoms were observed across the trial, Enanta said. All endpoints were met with "highly statistically significant" results, the company added.

The company also said EDP-323 was observed to be generally safe and well-tolerated, with no serious or severe adverse events, over a five-day dosing period and through 28 days of follow-up.

Shares of the company were up 3.2% in recent premarket activity.

Price: 11.01, Change: +0.34, Percent Change: +3.19